8 active not recruiting, 7 completed, 1 recruiting, 1 suspended. 14 Phase 1, 7 Phase 2, 1 Early Phase 1, 1 Not applicable.
Follow Unresectable Pancreatic Carcinoma: new trials by email Literature Review of Unresectable Pancreatic Carcinoma trials Research Report on Unresectable Pancreatic Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2023-05-22 | 2026-07-10 |
| Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy - Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 49 | 2022-11-16 | 2026-07-15 |
| A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel - Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified | Phase 1 / Phase 2 | Active not recruiting | Oncolytics Biotech | 122 | 2021-10-27 | 2026-05-19 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Dostarlimab, Niraparib, Biopsy - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | University of Washington | 18 | 2021-10-18 | 2026-08-20 |
| Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer Bosentan, Gemcitabine, Nab-paclitaxel - Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | Suspended | City of Hope Medical Center | 21 | 2021-09-01 | 2026-06-15 |
| Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas Entinostat, Molibresib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-09-18 | 2020-09-28 | |
| Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer Zinc - Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma | Not applicable | Completed | Emory University | 17 | 2019-04-17 | 2025-10-09 |
| Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer Hydroxychloroquine, Trametinib - Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer | Phase 1 | Terminated | University of Utah | 25 | 2019-01-30 | 2026-05-14 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Durvalumab, Guadecitabine - Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type | Phase 1 | Active not recruiting | University of Southern California | 55 | 2018-02-07 | 2026-06-01 |
| TAS102 in Combination With NAL-IRI in Advanced GI Cancers Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride - Colorectal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Emory University | 64 | 2018-01-30 | 2025-01-07 |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer XL888, Pembrolizumab - Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Emory University | 47 | 2017-07-07 | 2026-05-22 |
| Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study Endoscopic Ultrasound, Fluorescence Imaging, Photodynamic Therapy - Advanced Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma | Phase 2 | Completed | Mayo Clinic | 13 | 2017-05-31 | 2025-07-30 |
| Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients Tocilizumab, Gemcitabine, nab-Paclitaxel - Unresectable Pancreatic Carcinoma | Phase 2 | Completed | Herlev Hospital | 147 | 2017-01-26 | 2023-09-22 |
| Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 8 | 2016-10-18 | 2025-04-30 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 122 | 2016-08-31 | 2026-09-25 |
| M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Berzosertib, Biopsy Specimen, Biospecimen Collection - Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 66 | 2016-07-22 | 2026-09-25 |
| Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride - Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 21 | 2016-03-17 | 2026-10-19 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery AZD1775, Gemcitabine, Nab-paclitaxel - Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2014-08-19 | 2023-04-25 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis - Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2013-01-15 | 2017-08-22 |
Pancreatic Neoplasms (13) · Colorectal Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Neoplasm Metastasis (2) · Small Cell Lung Carcinoma (2) · Stomach Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Fallopian Tube Neoplasms (1) · Gallbladder Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1)
Neoplasms (15) · Neoplasms by Site (15) · Digestive System Diseases (14) · Digestive System Neoplasms (14) · Endocrine Gland Neoplasms (13) · Endocrine System Diseases (13) · Pancreatic Diseases (13) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Colonic Diseases (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms by Histologic Type (3) · Rectal Diseases (3) · Adenocarcinoma (2)
Albumin-Bound Paclitaxel (5) · Gemcitabine (5) · 130-nm albumin-bound paclitaxel (4) · Irinotecan (3) · Magnetic Resonance Spectroscopy (3) · Biopsy (2) · Disulfides (2) · Immunoglobulin G (2) · Specimen Handling (2) · Taxes (2) · durvalumab (2) · entinostat (2) · olaparib (2) · trifluridine tipiracil drug combination (2) · 1-phenyl-3,3-dimethyltriazene (1)
National Cancer Institute (NCI) (7) · Emory University (3) · City of Hope Medical Center (2) · Herlev Hospital (1) · Mayo Clinic (1) · Oncolytics Biotech (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Southern California (1) · University of Utah (1) · University of Washington (1)
United States (16) · Canada (3) · Denmark (1) · Germany (1) · Norway (1)
Olatunji B. Alese, MD (2) · Patricia M LoRusso (2) · Anthony El-Khoueiry, MD (1) · Conan Kinsey, MD (1) · Elizabeth M. Swisher (1) · Inna Chen, MD (1) · James Posey, MD (1) · Jennifer R Eads (1) · Joseph W Kim (1) · Liza C Villaruz (1) · Maria Diab, MD (1) · Nilofer Azad (1) · Olav Dajani, MD PhD (1) · Ravi Salgia (1) · Vaibhav Sahai (1)
PMID 25931518, PMID 33647286, PMID 34261044, PMID 39863139, PMID 40354592, PMID 42836590
UM1CA186689 (4), P30CA138292 (2), UM1CA186644 (2), P01CA084203 (1), P30CA006973 (1), P30CA014089 (1), P30CA046592 (1), R21CA172997 (1), U01CA070095 (1), U01CA132123 (1), U10CA021115 (1), U10CA180820 (1), UM1CA186688 (1), UM1CA186690 (1), UM1CA186691 (1)